Here’s one sign the affordability crisis isn’t what it used to be. You’ve probably seen the headlines.
Big win here for Trump, but also for free market competition.
- The Trump Administration has aggressively promoted direct-to-consumer sales and included PBM reforms in the Big Beautiful Bill.
- Team Trump has attracted a half trillion dollars in new biopharmaceutical investment to the US.
- Intense market competition is driving down the price of medicines, such as popular weight loss drugs.
Democrats and the media will try to credit Biden and the so-called Inflation Reduction Act, but the short list of drugs subject to Medicare price negotiations haven’t really moved the needle because individual plans had already aggressively negotiated prices.